21 – 30 of 89
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Effects of certain pre-analytical factors on the performance of plasma phospho-tau217
(
- Contribution to journal › Article
-
Mark
The impact of tau-PET in a selected memory clinic cohort : rationale and design of the TAP-TAU study
(
- Contribution to journal › Article
-
Mark
Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer’s disease, positive for plasma p-tau217
(
- Contribution to journal › Article
- 2023
-
Mark
The reporting of neuropsychiatric symptoms in electronic health records of individuals with Alzheimer’s disease : a natural language processing study
(
- Contribution to journal › Article
-
Mark
Cerebral Aβ deposition precedes reduced cerebrospinal fluid and serum Aβ42/Aβ40 ratios in the App NL−F/NL−F knock-in mouse model of Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Functional gradients of the medial parietal cortex in a healthy cohort with family history of sporadic Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Baseline structural MRI and plasma biomarkers predict longitudinal structural atrophy and cognitive decline in early Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Clinical outcomes up to 9 years after [18F]flutemetamol amyloid-PET in a symptomatic memory clinic population
(
- Contribution to journal › Article
-
Mark
Recruitment of pre-dementia participants : main enrollment barriers in a longitudinal amyloid-PET study
(
- Contribution to journal › Article
- 2022
-
Mark
Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer’s dementia in mild cognitive impairment patients
(
- Contribution to journal › Article